Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.